Lysophosphatidic acid (LPA), produced extracellularly by autotaxin (ATX), has diverse biological activities implicated in tumor initiation and progression, including increasing cell survival, angiogenesis, invasion and metastasis. ATX, LPA and the matrix metalloproteinase (MMP)-9 have all been implicated in hepatocellular carcinoma (HCC) invasion and metastasis. We, thus sought to determine whether ATX with subsequent LPA production and action, including induction of MMP-9 could provide a unifying mechanism. ATX transcripts and LPA receptor type 1 (LPA1) protein are elevated in HCC compared with normal tissues. Silencing or pharmacological inhibition of LPA1 significantly attenuated LPA-induced MMP-9 expression and HCC cell invasion. Further, reducing MMP-9 activity or expression significantly inhibits LPA-induced HCC cell invasion, demonstrating that MMP-9 is downstream of LPA1. Inhibition of phosphoinositide-3 kinase (PI3K) signaling or dominantnegative mutants of protein kinase Cd and p38 mitogenactivated protein kinase (MAPK) abrogated LPA-induced MMP-9 expression and subsequent invasion. We thus demonstrate a mechanistic cascade of ATX-producing LPA with LPA activating LPA1 and inducing MMP-9 through coordinate activation of the PI3K and the p38 MPAK signaling cascades, providing novel biomarkers and potential therapeutic targets for HCC.
Introduction
Hepatocellular carcinoma (HCC) is a primary liver malignancy that accounts for an estimated 600 000 deaths annually (Parkin et al., 2001) . The high mortality rate is largely a product of intrahepatic and distant metastasis occurring despite liver resection or transplantation. It is, thus critical to elucidate the mechanisms underlying HCC invasion and metastasis to implement effective therapeutic approaches that will reduce mortality.
Lysophosphatidic acid (1-or 2-acyl-lysophosphatidic acid, LPA) is a lipid mediator that is involved in multiple cellular events associated with tumor initiation and progression, including proliferation, survival, angiogenesis, motility, invasion and metastasis (Mills and Moolenaar, 2003) . LPA is produced extracellularly by autotaxin (ATX). ATX mRNA levels are elevated in HCC cells and ATX levels correlate with HCC development and metastasis, suggesting a role for LPA in the pathophysiology of HCC Zhao et al., 1999) . Compatible with the elevated ATX transcripts, increased LPA levels are present in the liver, bile and serum of patients with HCC compared with healthy individuals (Skill et al., 2009) . In addition, recent data indicate that ATX can promote HCC cell invasion (Wu et al., 2010) . As the activities of ATX appear to be due, primarily if not solely, to the production and action of LPA, the effect of LPA on HCC progression needs to be clarified. In support of this contention, similar to ATX, LPA has been shown to augment human HCC invasion (Wang et al., 2004) .
LPA binds to a series of cell-surface G proteincoupled receptors. So far, six subtypes of LPA receptors (LPA1-6) have been identified, and evidence for three additional LPA receptors has been presented (Brinkmann, 2007; Noguchi et al., 2009) . However, the expression of LPA receptors and their role, if any, in HCC progression remain to be determined.
In HCC, cancer cell invasion is associated with extensive remodeling of the extracellular matrix, angiogenesis and hepatocyte injury (McKenna et al., 2002) . Matrix metalloproteinases (MMPs), a large family of structurally related zinc-endopeptidases that degrade most of the components of extracellular matrix, are key mediators of these processes (Hidalgo and Eckhardt, 2001) . Among MMPs, MMP-9 (gelatinase B) has been postulated to have a critical role in HCC cell invasion and metastasis (Hayasaka et al., 1996) . MMP-9 levels are elevated in HCC compared with surrounding liver parenchyma and provide a prediction of the capacity of HCC to invade and metastasize (Arii et al., 1996) .
Despite data demonstrating elevation of ATX and LPA in HCC and the association of ATX and LPA with invasion and metastasis, the mechanisms underlying LPA-induced invasion of HCC are unknown. This gap in knowledge limits the ability to effectively target the processes regulating invasion and metastasis of HCC. We demonstrate, herein, that ATX transcript levels are elevated in HCC as compared with normal tissues. Furthermore, LPA1 levels are elevated in HCC and LPA1 is required for LPA-induced MMP-9 expression and invasion. LPA upregulates MMP-9 expression through both phosphoinositide 3-kinase (PI3K)/Akt and protein kinase Cd (PKCd)/p38 mitogen-activated protein kinase (MAPK) pathways. Moreover, LPAinduced MMP-9 expression is required for LPA-induced HCC cell invasion. Our results identify mechanisms by which LPA increases HCC cell invasion through MMP-9 production and action providing potential biomarkers and therapeutic targets that could be used to limit HCC invasion.
Results

LPA induces coordinate increases in HCC cell invasion and MMP-9 expression and activity
We utilized cDNA microarray analysis of 139 HCC and 81 normal liver tissues to compare the level of ATX mRNA expression in HCC and normal tissues. Similar to previous studies, albeit with a limited number of patients, we observed a greater than threefold increase of ATX mRNA levels in HCC as compared with normal tissue (Figure 1a) . The transcriptional profiling results were confirmed by quantitative RT-PCR (Supplementary Data S1).
As the effects of ATX are mediated by LPA, we determined the effect of increasing doses LPA on HCC cell migration and invasion. As shown in Figure 1b , LPA induced a dose-dependent increase in invasion of both SK-Hep1 and SNU-387 cells, albeit much more efficiently in SK-Hep1 than SNU-387 cells. To determine whether the effects of LPA on invasion of HCC cells was generalizable, we also assessed HLF and Focus HCC lines and compared the HCC lines with four ovarian cancer cells lines (CAOV-3, SKOV-3, DOV-13 and PA-1). Of the eight lines assessed (Supplementary Data S2), SK-Hep1 was most sensitive to the effects of LPA. However, for each of the other HCC lines, LPA induced a statistically significant increase in invasion in the HCC lines (SNU-387, HLF and Focus) that was comparable to that induced by LPA in the ovarian cancer cell lines. In support of the effect of LPA on invasion, LPA also markedly increased wound healing in SK-Hep1 cells (Supplementary Data S3).
As MMP-9 is a key regulator of HCC invasion, we determined the effect of LPA on MMP-9 expression and activity. LPA induced a dose-dependent increase in MMP-9 mRNA expression and activity in both SKHep1 and SNU-387 cells (Figures 1c and d) . In contrast, LPA did not induce detectable increases in MMP-2 levels and activity in HCC cells. Intriguingly, LPA did induce increase in MMP-2 in DOV-13 ovarian cancer cells providing a positive control and indicating lineage-specific effects of LPA. The dose response for LPA-induced invasion and MMP-9 expression and activation, as well as the differential sensitivity of SK-Hep1 and SNU-387 to LPA in terms of magnitude of response for both invasion and MMP-9 production and action was compatible with MMP-9 mediating the effects of LPA on invasion.
MMP-9 is required for LPA-induced HCC invasion Given the induction of the mRNA expression and activity of MMP-9 by LPA and the known role of MMP-9 in promoting cell invasion of HCC, we sought to determine whether silencing MMP-9 expression could prevent LPA-induced cell invasion. Therefore, we transfected the cells with MMP-9 small-interfering RNA (siRNA) and then stimulated the cells with LPA. Treatment of the cells with MMP-9 but not with control siRNA significantly reduced MMP-9 levels and activity The cells were transfected with the indicated siRNAs for 48 h, followed by invasion assay with 5 mM LPA in the bottom chamber of the invasion assay kit for 24 h (left). The cells were incubated with either normal IgG or anti-MMP-9 antibody for 1 h, followed by invasion analysis with 5 mM LPA in the bottom chamber of the invasion assay kit for 24 h (right). Results show the mean±s.d. of one of three independent experiments in triplicate with similar results. *Po0.05.
(Akt inhibitor), p38 MAPK (SB203580) and PKC (rottlerin and bisindolylmaleimide I) attenuated LPAinduced MMP-9 activity (Figure 3a) , as well as HCC cell invasion ( Figure 3b ). However, we did not observe any detectable inhibition of MMP-9 activity or HCC cell invasion by inhibitors of MEK (PD98059) and JNK (SP600125), indicating a role for the PI3K and p38 MAPK pathways in LPA-induced MMP-9 action and cellular invasion.
Next, we examined the effect of LPA on phosphorylation of PKC isoforms, Akt and p38 MAPK to further elucidate the mechanism(s) by which LPA induces HCC invasion. In HCC cells, LPA increased PKCd (Thr-505), p38 MAPK and Akt phosphorylation but not phosphorylation of other PKC isoforms (Figure 4a ). To determine whether PKC activation is required for p38 MAPK and Akt phosphorylation, we pretreated SK-Hep1 cells with pharmacological inhibitors of PKC and then stimulated the cells with LPA. Rottlerin and bisindolylmaleimide I efficiently blocked LPA-induced p38 MAPK phosphorylation (Figure 4b) . Inhibition of the PI3K pathway with LY294002 or the Akt inhibitor did not alter p38 phosphorylation, indicating that the PI3K pathway is not upstream of LPA-induced p38 MAPK activation. Further, rottlerin or bisindolylmaleimide I did not alter LPA-induced Akt phosphorylation (Figure 4b ). Thus, although PKC is not required for LPA-induced Akt phosphorylation, PKC is located upstream of LPA-induced p38 MAPK activation. We utilized dominant-negative (DN) mutants to further explore the role of PKCd and p38 MAPK in LPAinduced MMP-9 activation and HCC cell invasion. Transfection of SK-Hep1 cells with DN-PKCd significantly inhibited LPA-induced phosphorylation of p38 MAPK, confirming the location of PKCd as upstream of p38 MAPK in the LPA signaling cascade (Figure 5a ). In addition, both DN-PKCd and DN-p38 MAPK markedly reduced MMP-9 mRNA expression and activity (Figure 5b ), as well as LPA-induced SK-Hep1 cell invasion (Figure 5c ).
LPA1 is required for LPA-mediated HCC invasion
Given that the endothelial differentiation gene (EDG) LPA receptor family (LPA1, LPA2 and LPA3) expression has been linked to tumorigenesis, invasion and metastasis (Yu et al., 2008; Liu et al., 2009) , we examined the expression of LPA receptors in HCC cells. The data from quantitative RT-PCR showed significantly higher levels of LPA1 mRNA expression than LPA2 or LPA3 (Figure 6a) . Next, to compare the expression of LPA1 in normal and HCC clinical samples, we performed immunohistochemical staining of a tissue array containing 47 HCC tumor samples with anti-LPA1 antibody. Previous studies have demonstrated that activated LPA1 is rapidly translocated into the cytosol (Murph et al., 2003) , thus we assess both cytoplasmic and cellular membrane levels of LPA1 as an indication of expression and activity. LPA1 was detected in the cytoplasm and cellular membrane of HCC, although it was not detectable in all normal liver tissues examined. LPA1 expression was variable (no staining: 36.2% of samples; weak staining: 23.4%; moderate staining: 25.5%; and strong staining: 14.9%). Membranous or cytoplasmic expression of LPA1 was observed in 64% (30/47) of HCC tissues (Figure 6b) .
Next, we pretreated the cells with an LPA1 and LPA3 antagonist Ki16425 to determine whether the LPA1 receptor was required for LPA-induced HCC invasion. Ki16425 treatment inhibited both LPA-induced MMP-9 upregulation as well as HCC cell invasion (Figure 7a ). To confirm a critical role of LPA1 in LPA-induced HCC progression, we transfected the cells with LPA1, LPA2 and LPA3-specific siRNA and then assessed effects on LPA-induced MMP-9 activity and invasion. Each 
Discussion
In our current study, we elucidate the underlying mechanisms by which LPA augments invasion of HCC cells. First, we demonstrated that ATX and LPA1 levels are higher in HCC than in normal liver tissues. Using HCC cell line models, we demonstrated that LPA increased MMP-9 activity through the LPA1 receptor, inducing a signaling cascade that is critical for LPAinduced HCC cell invasion and migration. LPA-induced activation of both the PKCd/p38 MAPK and PI3K/Akt signaling pathways is required for MMP-9 expression and activation, as well as HCC cell invasion. These findings suggest a critical role for LPA in HCC progression through coordinate activation of LPA1 and the important proteolytic enzyme MMP-9.
Accumulating data support a critical role of MMP-9 in HCC cell invasion and metastasis. Elevated MMP-9 levels in HCC cells are associated with increased tumor recurrence or metastasis after tumor resection (Jiang et al., 2000) . Our data supports a contention that elevated levels of LPA as a consequence of increased ATX in HCC contributes to elevated MMP-9 level in HCC tumor and subsequent cell invasion and metastasis. First, ATX levels are elevated in HCC and in the product of ATX; LPA increases both MMP-9 levels and activity in HCC cell lines. Second, silencing of MMP-9 expression abolished LPA-induced HCC cell invasion. Consistent with this finding, blocking MMP-9 activity with a MMP-9 neutralizing antibody also attenuated LPA-induced invasion. Third, the LPA concentration curves and signaling pathways for MMP-9 expression were coordinate with LPA-induced HCC cell invasion. In addition, blocking the PI3K pathway, PKCd or p38 MAPK demonstrated similar effects on both MMP-9 expression as well as HCC cell invasion. Finally, LPA1 was required for both MMP-9 activity and HCC invasion. Thus, MMP-9 is a critical downstream mediator of LPA-induced invasion of HCC cells.
LPA has been demonstrated to link to different downstream kinase cascades in a tissue-specific manner. We previously demonstrated that LPA increases HIF-1a expression by activating PI3K and MAPK signals in SK-Hep1 HCC cells (Lee et al., 2006a) . These PI3K and MAPK signals also have been suggested as major pathways for MMP-9 expression (Chung et al., 2004) . Our current data show the involvement of PI3K/Akt and p38 MAPK but not the MEK/ERK pathways in LPA-induced MMP-9 expression and activity. Simon et al. (1998) have demonstrated that p38 MAPK is more critical than p42/p44 MAPK for heregulin-b1-induced MMP-9 induction in breast cancer cells, consistent with our results with LPA-induced MMP-9 induction in HCC cells. Previous reports (Liu et al., 2002; Woo et al., 2004) have implicated PKCd in the induction of MMP-9 expression and invasion of HCC cells. Our studies suggest that LPA-induced MMP-9 expression and activation, as well as invasion of HCC cells are also dependent on PKCd. It is of note that PI3K and p38 MAPK signals may contribute to HCC invasion through both MMP-9 dependent and independent processes, as their roles in regulating MMP-9 activity was less than their requirement for invasion.
The effect of LPA1 expression on tumor progression seems to depend on tumor lineage and the relative expression of specific EDG family LPA receptors. LPA1 is overexpressed compared with LPA2 or LPA3 and has been implicated in motility, invasion and metastasis of lung, breast and colon cancer cells (Shida et al., 2003; Hama et al., 2004; Yamada et al., 2004) . However, ovarian cancer show a significant reduction in LPA1 levels as compared with normal tissues . In addition, LPA2 and LPA3 appear to have a greater role in ovarian cancer aggressiveness as compared with LPA1 (Sengupta et al., 2003; Ren et al., 2006; Murph et al., 2008; Yu et al., 2008 ). In our current study, we demonstrated higher levels of LPA1 transcripts in HCC cells than that of LPA2 or LPA3. Tissue microarray data from HCC tissues also demonstrated elevated levels of LPA1 protein as compared with normal liver tissues. We observed that pharmacological inhibition and silencing of LPA1 profoundly attenuated MMP-9 expression and HCC cell invasion, suggesting a critical role for LPA1 in HCC progression. In support of our results, a recent study showed that silencing the LPA1 receptor in breast and ovarian cancer cells implanted in mice significantly reduced the incidence of bone metastasis (Boucharaba et al., 2006) .
In conclusion, our results demonstrate that LPA increases HCC cell invasion through activation of LPA1 and subsequent production of MMP-9. Both PI3K/Akt and PKCd/p38 MAPK pathways are required for LPAinduced upregulation of MMP-9 levels and activity and subsequent invasion. Therefore, LPA1 and MMP-9 and potentially the PI3K/Akt and PKCd/p38 MAPK pathways may represent useful targets to reduce invasion and metastasis of HCC, potentially improving outcomes for this devastating disease.
Materials and methods
Reagents LPA was obtained from Avanti Polar Lipids (Alabaster, AL, USA). LY294002, Akt inhibitor, PD98059, SB203580, SP600125, rottlerin and bisindolylmaleimide I were from Calbiochem (Darmstadt, Germany). (a) SK-Hep1 HCC cells were serum-starved for 24 h. Cells were pretreated with Ki16425 for 1 h, followed by stimulation with 5 mM LPA for 24 h. MMP-9 protein activity was determined by zymography (above). SK-Hep1 HCC cells were pretreated with Ki16425 for 1 h, followed by invasion analysis with 5 mM LPA in the bottom chamber of the invasion assay kit for 24 h (below). Cell culture All HCC cell lines were obtained as described previously (Zimonjic et al., 1999) and maintained in Dulbecco's modified Eagle's medium/F12 medium supplemented with glutamine (2 mmol/l) and 5% fetal bovine serum. CAOV-3 and SKOV-3 cells were maintained in RPMI 1640, DOV-13 in Dulbecco's modified Eagle's medium and PA-1 in Eagle's minimum essential medium supplemented with 5% fetal bovine serum in a humidified atmosphere containing 5% CO 2 at 37 1C.
Gene expression data For analysis of expression of ATX mRNA in HCC tissues, we used previously published microarray data (Lee et al., 2006b) . Briefly, total RNAs isolated from frozen liver tissue (139 HCC and 81 matched nontumor surrounding liver tissues, GEO accession IDs: GSE1898 and GSE4024) were used to generate gene expression data. The microarray experiments were run on all tissues. To obtain gene expression profile data from human liver tissues, 20 mg of total RNAs from tissues were used to generate fluorescently (Cy-5 or Cy-3)-labeled cDNA and hybridized to oligonucleotide microarrays produced in the National Cancer Institute (Lee et al., 2006b) . At least two hybridizations were carried out for each tissue using a dyeswap strategy to eliminate dye-labeling bias. Total RNAs from 19 normal livers were pooled and used as the reference for all microarray experiments.
siRNA and plasmid transfection siRNAs of LPA receptors and MMP-9 were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Negative siRNAs were obtained as described (Lee et al., 2006a) . DN-p38 MAPK mutant construct was kindly provided by Dr Surh (Seoul National University, Seoul, Korea) . DN-PKCd adenovirus was provided by Dr Hur (Chungnam National University, Daejeon, Korea) (Byun et al., 2008) . Cells were transfected according to the manufacturer's instructions with Lipofectamine 2000 transfection reagent obtained from Invitrogen (Carlsbad, CA, USA).
Real-time (RT)-PCR quantification
Quantitative RT-PCR was performed as previous described (Liu et al., 2009) . Briefly, total cellular RNA was isolated using RNeasy Protect Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. Taqman probes and Taqman One-Step RT-PCR master reagent were obtained from Applied Biosystems (Foster City, CA, USA). Human ATX, MMP-2 and -9 and LPA1, -2, -3 levels were determined using Taqman RT-PCR using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems).
Immunoblotting Cells lysates were prepared as described (Lee et al., 2006a) . Antibodies used in the study were phospho-PKC antibody sampler kit, phospho-p38 MAPK and phospho-Akt from Cell Signaling (Danvers, MA, USA). Antibodies for total Akt and p38 MAPK were from Santa Cruz Biotechnology. MMP-9 antibody was from Calbiochem. The immunoreactive bands were visualized by ECL (LAB-Frontier, Seoul, Korea) using ImageQuant 300 (GE Healthcare, Buckinghamshire, UK).
In vitro invasion assay Invasion assay kit with Matrigel-coated inserts (BD Biosciences, San Jose, CA, USA) was used with 8 mm pore size filters. Volume of 1 Â 10 5 cells/well were added to the upper compartment of the invasion chamber, with or without pharmacological inhibitors. To the lower compartment, we added serum-free conditioned medium with or without LPA. After incubation for 24 h at 37 1C, filters were fixed and stained with Diff-Quik reagents (Dade Begring, Inc., Newark, DE, USA). The values obtained were calculated using the number of invaded cells from three filters.
Gelatin zymography assay
The concentrated conditioned medium was electrophoresed by 10% SDS-PAGE gel containing 0.1% (w/v) gelatin. After washing with 2.5% Triton X-100, the gels were incubated in 10 mM CaCl 2 , 0.01% NaN 3 and 50 mM Tris-HCl (pH 7.5) overnight at 37 1C. The gel was stained with 0.25% Coomassie Blue for 1 h and destained in methanol/acetic acid. Gelatinolytic activity was manifest as horizontal white bands on a blue background.
Patients and tumor samples for tissue microarray Tissue samples from 47 patients undergoing elective surgery for HCC at Chungnam National University Hospital, Daejeon, Korea, between 2003 and were used to generate a tissue microarray. The patient population included 37 men and 10 women, ranging in age from 45 to 71 years (mean, 58 years). Patients had histologically confirmed HCC. No patients had received preoperative chemotherapy. All protocols were approved by the Institutional Review Board.
Tissue microarray construction and immunohistochemistry
Paraffin blocks of 47 human HCC were identified on corresponding hematoxylin and eosin-stained sections. Areas of interest that represented non-necrotic invasive HCC were identified and then were marked on the donor block. The donor block was cored, and a 2-mm core was transferred to the recipient 'master block' using the Tissue Microarrays (Meditech, Gunpo, Korea). Two cores of HCC were arrayed per specimen. Four cores of normal liver tissue were also sampled. Immunohistochemistry was performed as described (Seo et al., 2008) . Membranous or cytoplasmic staining was considered as positive cells. Immunohistochemical staining was scored according to intensity, and tumors were classified into four grades based on staining intensity (grade 0, no staining intensity; grade 1, weak staining intensity; grade 2, moderate staining intensity; grade 3, strong staining intensity). In the case of heterogeneous sample staining, the higher score was chosen if more than 50% of the cells showed greater staining intensity.
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